SHATTUCK LABS INC

Company Overview

Shattuck Labs (STTK) is a clinical‑stage biotechnology company developing engineered TNF‑receptor therapeutics, with a lead DR3 antagonist monoclonal antibody SL‑325 targeting inflammatory bowel disease (ulcerative colitis and Crohn’s). The program has favorable preclinical toxicology and PK/RO modeling, an IND planned for Q3 2025 and Phase 1 enrollment targeted by Q2 2026; operations are capital‑intensive, milestone‑driven and supported by a small workforce (44 FTE) and outsourced manufacturing (single CMO). Management reports an accumulated deficit, modest cash on hand and a runway into 2027 absent additional financings; recent collaboration terminations and a planned contingent private placement tied to IND clearance are material near‑term developments. Competitive TL1A/DR3 landscape, single‑source manufacturing and reliance on third‑party CROs/CMOs are key operational concentrations that drive near‑term investor focus.

Executive Compensation Practices

As a small, pre‑revenue biotech in the Healthcare / Biotechnology (Pharmaceutical Products) industry, executive pay at Shattuck is likely equity‑heavy and milestone‑linked: lower cash salaries, stock options/RSUs and performance or retention awards tied to IND/clinical milestones, financing events, or strategic partnerships. The company explicitly recognizes stock‑based compensation using Black‑Scholes/Monte Carlo methodologies, so grant sizes, volatility assumptions and vesting tied to SL‑325 progress materially affect both reported G&A and executive wealth. Cost control actions (program discontinuations and headcount reductions) that reduced R&D in 2024–2025 may have shifted short‑term bonus opportunities toward long‑dated equity incentives to conserve cash. The private placement that includes director‑designation rights could alter board composition and future compensation mixes if new investors seek representation or different incentive structures.

Insider Trading Considerations

Material clinical and financing milestones (IND filing, Phase 1 enrollment, trial readouts, and private placement closings) are likely to produce clustered insider activity because these events are both material and value‑creating or dilutive. Given a small senior team and concentrated operational control, insider purchases or sales will be more visible and may signal management’s view of SL‑325’s prospects or personal liquidity needs (e.g., option exercises to cover taxes). Expect standard regulatory constraints (Section 16 reporting, Form 4s, blackout windows around material non‑public events) and common use of pre‑arranged 10b5‑1 plans at small biotechs to provide planned liquidity; monitor timing of any insider sales relative to announced IND/financing milestones for potential market sensitivity. Finally, because the company depends on external capital, insider transactions around financing announcements, warrant exercises or director changes tied to the private placement merit close attention for dilution and governance implications.